Reconstructing the immune system with lentiviral vectors

Area of Science:

• * Gene therapy and immunology
• * Viral vector development
• * Cellular immunotherapy

Background:

• * Lentiviral vectors (LVs) have advanced from research to clinical trials with strong safety and efficacy.
• * LVs offer significant advantages over other viral vector systems for enhancing human immunity.
• * Robust and persistent transduction of blood cells by LVs supports broad immune therapeutic applications.

Purpose of the Study:

• * To review the development and clinical applications of lentiviral vectors for immune enhancement.
• * To discuss technological adaptations for ex vivo cell manipulation in lentiviral therapies.
• * To explore the potential of in vivo lentiviral administration for future immune therapies.

Main Methods:

• * Review of lentiviral vector applications in pre-clinical and clinical research.
• * Discussion of ex vivo cell engineering techniques for immune cell therapies.
• * Analysis of strategies for in vivo lentiviral vector targeting.

Main Results:

• * Lentiviral vectors demonstrate remarkable safety and efficacy in clinical trials.
• * Engineered T cells (CARs, TCRs) and dendritic cells show promise for cancer and chronic infection therapies.
• * Lentiviral vectors enable targeting of various immune cells, including stem cells, lymphoid, and myeloid cells.

Conclusions:

• * Lentiviral vectors are a powerful tool for developing advanced immune therapies.
• * Ex vivo cell manipulation technologies are crucial for current lentiviral-based treatments.
• * In vivo lentiviral vector administration is a key future direction for off-the-shelf immune therapies.